Trial Profile
A Phase IIa, Multicenter, Treatment Assigned, Open-Label, Long-Term Extension Study To Determine Safety, Tolerability And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease(B2571001)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Vanutide cridificar (Primary) ; QS 21
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 17 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 21 Jan 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record..
- 09 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.